| Name | Kallikrein-4 | ||
| UniProt ID | KLK4_HUMAN | ||
| Gene Name | KLK4 | ||
| Gene ID | 9622 | ||
| Synonyms |
KLK4, AI2A1, ARM1, EMSP, EMSP1, KLK-L1, PRSS17, PSTS, kallikrein
|
||
| Sequence |
MATAGNPWGWFLGYLILGVAGSLVSGSCSQIINGEDCSPHSQPWQAALVMENELFCSGVL
VHPQWVLSAAHCFQNSYTIGLGLHSLEADQEPGSQMVEASLSVRHPEYNRPLLANDLMLI KLDESVSESDTIRSISIASQCPTAGNSCLVSGWGLLANGRMPTVLQCVNVSVVSEEVCSK LYDPLYHPSMFCAGGGQDQKDSCNGDSGGPLICNGYLQGLVSFGKAPCGQVGVPGVYTNL CKFTEWIEKTVQAS |
||
| Pathway Map | MAP LINK | ||
| KEGG ID | hsa9622 | ||
| TTD ID | T79400 | ||
| Pfam | PF00089; PF09342; PF13241; PF13365 | ||
| Pair Name | Acteoside, Sorafenib | |||
| Phytochemical | Acteoside | |||
| Drug | Sorafenib | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Regulate Info | Down-regulation | Kallikrein-4 | Expression | |
| Result | Acteoside exerts an antitumor effect possibly through its up-regulation of p53 levels as well as inhibition of KLK expression and angiogenesis. Acteoside could be useful as an adjunct in the treatment of advanced HCC in the clinic. | |||
